- Home
- CUE vs KPTI Comparison
CUE vs KPTI Comparison
Compare CUE & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- KPTI
- Stock Information
- Founded
- CUE 2014
- KPTI 2008
- Country
- CUE United States
- KPTI United States
- Employees
- CUE N/A
- KPTI N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- KPTI Health Care
- Exchange
- CUE Nasdaq
- KPTI Nasdaq
- Market Cap
- CUE 61.1M
- KPTI 44.5M
- IPO Year
- CUE 2018
- KPTI 2013
- Fundamental
- Price
- CUE $0.80
- KPTI $5.93
- Analyst Decision
- CUE Strong Buy
- KPTI Strong Buy
- Analyst Count
- CUE 2
- KPTI 7
- Target Price
- CUE $3.00
- KPTI $31.71
- AVG Volume (30 Days)
- CUE 283.3K
- KPTI 303.0K
- Earning Date
- CUE 11-13-2025
- KPTI 11-04-2025
- Dividend Yield
- CUE N/A
- KPTI N/A
- EPS Growth
- CUE N/A
- KPTI N/A
- EPS
- CUE N/A
- KPTI N/A
- Revenue
- CUE $8,286,000.00
- KPTI $137,269,000.00
- Revenue This Year
- CUE N/A
- KPTI $3.40
- Revenue Next Year
- CUE N/A
- KPTI $9.69
- P/E Ratio
- CUE N/A
- KPTI N/A
- Revenue Growth
- CUE N/A
- KPTI N/A
- 52 Week Low
- CUE $0.54
- KPTI $3.51
- 52 Week High
- CUE $1.99
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- CUE 53.24
- KPTI 48.25
- Support Level
- CUE $0.78
- KPTI $5.52
- Resistance Level
- CUE $0.96
- KPTI $6.22
- Average True Range (ATR)
- CUE 0.06
- KPTI 0.55
- MACD
- CUE 0.01
- KPTI -0.04
- Stochastic Oscillator
- CUE 39.12
- KPTI 66.67
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.